Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Aliona Filimonava
Observed name:
A. Filimonava
OpenAlex ID:
A5000117700
Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial
2024
·
Sergei Krasny
, Yauheni Baranau
, et al.
·
Frontiers in Oncology
·
8
PDF
Randomized Phase Ii Study of P62/sqstm1-encoding Plasmid (elenagen) in Combination With Gemcitabine for Platinum-resistant Ovarian Cancer
2026
·
Sergei Krasny
, Yauheni Baranau
, et al.
·
International Journal of Gynecological Cancer
·
1
Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial
2026
·
Sergei Krasny
, Yauheni Baranau
, et al.
·
International Journal of Gynecological Cancer
·
1
PDF
Effects of the baseline prognostic factors on efficacy of the p62/SQSTM1-encoding plasmid combined with gemcitabine in patients with recurrent platinum-resistant ovarian cancer.
2023
·
Alexander Shneider
, Sergey Polyakov
, et al.
·
Journal of Clinical Oncology
·
1
Randomized controlled trial of Elenagen (plasmid encoding p62/SQSTM1) plus gemcitabine versus Placebo plus gemcitabine in patients with platinum-resistant ovarian cancer
2026
·
Gabriel Levin
, Sergei Krasny
, et al.
·
Gynecologic Oncology
538P Adding plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy increases PFS for patients with platinum-resistant ovarian cancer (updated data)
2022
·
Y. Baranau
, S. Polyakov
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
6
Citation count:
11
H-index:
1
I10-index:
Year
Topic
Type